Search company, investor...

ArtemiLife

artemilife.com

Founded Year

2019

Stage

Unattributed | Alive

Total Raised

$300K

Last Raised

$300K | 3 yrs ago

About ArtemiLife

ArtemiLife scientists develop a range of food and beverage products that harness the full potential of, Artemisia annua, an ancient plant.

Headquarters Location

2093 Philadelphia Pike #1621

Claymont, Delaware, 19703,

United States

Missing: ArtemiLife's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ArtemiLife's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest ArtemiLife News

Could farmers be a part of fighting cancer?

Jun 5, 2020

The University of Kentucky and ArtemiLife Inc. will collaborate on a clinical study using the extract of a medicinal plant grown in Kentucky to test for anti-cancer activity of Artemisia annua and to determine the recommended dose of Artemisia annua for future clinical trials. The clinical study, conducted by the UK Markey Cancer Center , will focus on women with ovarian cancer. The study will assess the biomarker influence and kinetics of Artemisia annua extract utilizing ArtemiLife’s tea and coffee products. “Our team has brought Kentucky-grown Artemisia annua from the field, to the laboratory, and now to our patients with ovarian cancer,” said Jill Kolesar, cancer researcher and director of the Precision Medicine Clinic at the UK Markey Cancer Center. ArtemiLife Inc. and agriculture company ArtemiFlow USA have been working with the UK College of Agriculture, Food and Environment , and the Kentucky Tobacco and Research Development Center (KTRDC) under a cooperative agreement for the last three years to research how Artemisia annua grows in Kentucky and to explore the plant’s similarities to tobacco crops. “The University of Kentucky has been a great partner and asset as we continue exploring Artemisia annua. Collaborating with the Agriculture Department and the Markey Cancer Center in parallel has quickly generated a lot of momentum,” said ArtemiLife CEO Adam J. Maust. “The opportunity to focus on ovarian cancer is a great start for this first clinical study and the results will hopefully lead to additional cancer studies,” said Maust. Patients will take a series of ArtemiLife tea and coffee formulations that include Artemisia annua over the course of 30 days. The assessment will include measuring downstream biomarkers, monitoring adverse effects and assessing disease progression. Traditionally, Artemisia annua has been used by extracting the compound Artemisinin from the natural plant. Treatments containing an artemisinin derivative, artemisinin-based combination therapies, are now standard treatments in many parts of the world for malaria. Related

ArtemiLife Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ArtemiLife Rank

ArtemiLife Frequently Asked Questions (FAQ)

  • When was ArtemiLife founded?

    ArtemiLife was founded in 2019.

  • Where is ArtemiLife's headquarters?

    ArtemiLife's headquarters is located at 2093 Philadelphia Pike, Claymont.

  • What is ArtemiLife's latest funding round?

    ArtemiLife's latest funding round is Unattributed.

  • How much did ArtemiLife raise?

    ArtemiLife raised a total of $300K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.